Hikma Pharmaceuticals Deal History & Licensing Activity
Hikma Pharmaceuticals is a large pharma headquartered in UK. The company currently has 4 active clinical trials, primarily in Hematological Malignancies.
Deals (12mo)
3
Active Trials
4
Top Modality
N/A
Focus Area
Hematological Malignancies
Hikma Pharmaceuticals Pipeline Focus
Therapeutic areas and modalities where Hikma Pharmaceuticals is most active based on deal history and clinical trial data.
Therapeutic Areas
Hikma Pharmaceuticals Strategic Signals
Key indicators of Hikma Pharmaceuticals's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Strategic Profile
Acquisition Appetite
Strategic Priorities
Hikma Pharmaceuticals Clinical Pipeline
Hikma Pharmaceuticals has 4 active clinical trials across 2 development phases.
1
Not Applicable
3
Unknown
See How Your Asset Matches Hikma Pharmaceuticals's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Hematological Malignancies assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
About Hikma Pharmaceuticals Licensing & Deal Activity
Hikma Pharmaceuticals is a large pharma company based in UK that has been actively engaged in licensing transactions across the biopharma landscape.
Key therapeutic areas of focus for Hikma Pharmaceuticals include Hematological Malignancies (2 deals and trials), Autoimmune (1 deal and trial), and Infectious (1 deal and trial).
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Hikma Pharmaceuticals and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Hikma Pharmaceuticals's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.